Medical progress is facing a crisis: the significant investments into the development of new therapies in recent years have not resulted in an increase in approvals of innovative drugs. The number of newly launched medications has already been stagnating for some time, although pharmaceutic ... more
Dr. Matthias Urmann
Sanofi-Aventis Deutschland GmbH
Matthias Urmann studied chemistry at Heidelberg University. After a post-doctorate at Harvard University, he began his industrial career in pharmaceutical research at Hoechst AG (Frankfurt) in 1993. Here, he worked mainly in the research of new drugs for the treatment of the metabolic diseases, diabetes and adipositas, but he was also able to contribute to several drug candidates in the areas of arteriosclerosis and thrombosis. In the role of Associate Vice President, he has been responsible for managing a R&D Department within the Diabetes Division of Sanofi in Frankfurt since the beginning of 2010.